A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe | Journal of Experimental & Clinical Cancer Research | Full Text

A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe | Journal of Experimental & Clinical Cancer Research | Full Text

A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe

DCZ3301, a novel aryl-guanidino compound previously reported by our group, exerts cytotoxic effects against multiple myeloma (MM), diffused large B cell lymphoma (DLBCL), and T-cell leukemia/lymphoma. However,...

Authors:Liangning Hu, Bo Li, Gege Chen, Dongliang Song, Zhijian Xu, Lu Gao, Mengyu Xi, Jinfeng Zhou, Liping Li, Hui Zhang, Qilin Feng, Yingcong Wang, Kang Lu, Yumeng Lu, Wenxuan Bu, Houcai Wang…

Citation:Journal of Experimental & Clinical Cancer Research 2020 39:105

Content type:Research

 

Published on: 9 June 2020

• ViewFull Text
 
• ViewPDF